The Edwards Lifesciences Corporation (NYSE: EW) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a structural heart medical device manufacturer. These filings, sourced from the SEC’s EDGAR system, include current reports on material events, earnings announcements, capital markets activity and other items relevant to shareholders and analysts.
Edwards Lifesciences uses Form 8‑K to report developments such as quarterly financial results, financial guidance updates, leadership transitions, accelerated share repurchase agreements and legal or regulatory matters. Recent 8‑K filings, for example, describe third‑quarter financial results, a planned chief financial officer transition, an accelerated share repurchase agreement and legal proceedings related to the Federal Trade Commission’s successful motion to block the proposed acquisition of JenaValve Technology.
In addition to current reports, investors typically review Edwards’ annual reports on Form 10‑K and quarterly reports on Form 10‑Q, which provide detailed information on its structural heart portfolio, risk factors, research and development spending, and segment performance across transcatheter aortic valve replacement, transcatheter mitral and tricuspid therapies and surgical heart valves. Proxy statements on Schedule 14A and beneficial ownership or insider trading reports on Forms 3, 4 and 5 offer further insight into governance and executive equity activity.
Stock Titan enhances these filings with AI‑powered summaries that explain key points in accessible language, highlight important changes from prior periods and help readers interpret complex sections. Real‑time updates ensure that new Edwards Lifesciences filings appear promptly, while AI‑generated overviews of 10‑K, 10‑Q and Form 4 documents can assist users in quickly understanding the implications of lengthy disclosures and insider transactions without replacing their own review of the original filings.
Wellington Management reports beneficial ownership of 19,826,483 shares of Edwards Lifesciences common stock, equal to 3.38% of the class. The filing shows shared voting power of 18,601,111 shares and shared dispositive power of 19,826,483 shares, while sole voting and dispositive power are reported as zero. The securities are owned of record by clients of Wellington investment advisers.
The filing names the reporting entities (Wellington Management Group LLP; Wellington Group Holdings LLP; Wellington Investment Advisors Holdings LLP) and lists the Wellington investment advisers that control the client accounts. It also includes a certification that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Edwards Lifesciences (EW) Q2 2025 10-Q highlights
Net sales rose 12% YoY to $1.53 bn, driven by transcatheter valve therapies, lifting 1H revenue to $2.95 bn (+9%). Gross margin slipped 240 bp to 77.5% on mix and higher manufacturing cost, but operating income still advanced 12% to $411 m helped by $21 m of TSA income from the September 2024 Critical Care divestiture. A $47 m impairment on an unexercised acquisition option and a sharply higher tax provision ($64 m vs $20 m) cut continuing-ops net income 8% to $336 m; diluted EPS fell to $0.56 (-8%).
Discontinued operations (Critical Care & one minor product line) logged a $4 m loss vs a $1 m profit last year. Combined, GAAP net income attributable to EW declined 9% to $333 m.
Cash & balance sheet
- Operating cash flow surged 79% YoY to $571 m on working-capital improvements.
- Cash & equivalents climbed to $3.27 bn; total liquidity (cash + ST investments) is $4.06 bn.
- Total liabilities fell 4% to $2.88 bn; net cash position of ~$2.7 bn.
Capital allocation & restructuring
- Repurchased $264 m of stock (-3% share count YoY); treasury stock at cost now $6.46 bn.
- Realignment severance reserve down to $10 m; majority of payments due 2H 25.
Key takeaways: Top-line momentum and robust cash generation underline core valve franchises, while EPS was pressured by non-recurring impairment and taxes. Post-divestiture focus on structural-heart pipeline and optionality from sizeable cash balance remain central to the investment case.
Edwards Lifesciences (EW) – Form 4 insider transaction
Company Vice President, JAPAC, Daniel J. Lippis reported the sale of 4,114 EW common shares on 07/28/2025. Trades were executed in multiple lots at prices between $79.45 and $79.47, producing a weighted-average sale price of $79.4605. Following the sale, Lippis’ direct beneficial ownership stands at 22,001.9103 shares. No derivative transactions were reported and no other changes in ownership were disclosed.
The filing is limited to this single transaction; it does not detail additional holdings or option grants. Form 4 timing complies with SEC rules, indicating the trade likely settled on, or shortly before, the reported date.